Nob Hill Therapeutics, Inc. is a Delaware corporation headquartered in Albuquerque, New Mexico. The company specializes in creating innovative inhalation therapies, including the development of DryNeb, a first-in-kind dry powder product to improve lung treatments.
Subscribe to see Nob Hill Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Nob Hill Therapeutics, Inc. is a biotechnology company headquartered in United States. Its most recent funding round, Series A, raised $1.8M in July 2024. Xcout tracks 8 named people at Nob Hill Therapeutics, Inc., including Noel Greenberger (Chief Executive Officer).
2 more named people on record for Nob Hill Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $1.8M | 3 named | |
| — | $100,000 | 3 named | |
| SEC Form D filing | $50,000 | — | |
| SEC Form D filing | $75,000 | — | |
| SEC Form D filing | $143,545 | — | |
| SEC Form D filing | $250,000 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Nob Hill Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Nobilis Therapeutics, Inc. is a Delaware C-corporation headquartered in Portland, Oregon, focused on the therapeutic uses of inert gas mixtures and portable delivery devices.
VERO Biotech Inc. is an emerging biotechnology company focused on the design and delivery of inhaled nitric oxide systems such as GENOSYL, with headquarters located in Georgia.
Bexson Biomedical is a US-based biopharmaceutical company situated in Santa Barbara, California, focused on the research and development of non-opioid therapeutics and drug delivery systems.
NovoThelium is a privately held biotechnology startup based in San Antonio, Texas, that is developing a tissue-engineered matrix for nipple regeneration following mastectomies.
Eyenovia, Inc. is a New York-based ophthalmic technology and pharmaceutical manufacturing company focused on targeted drug-delivery solutions for eye care using its proprietary Optejet device.
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.